Sangamo Therapeutics Received U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

Click here to view

Presentation

Process and Platform Development for Production and Purification of CNS-Tropic Engineered AAV Capsids

Download PDF